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Purpose: Atherosclerotic plaque vulnerability is a systemic phenomenon
and is often associated with severe plaque infiltration with inflammatory cells.
18-Fluoro-deoxyglucose (FDG) accumulates in inflammatory cells of athero-
sclerotic plaques. The aim of this study was to assess whether 1) FDG uptake
in the aorta and carotid arteries measured by positron emission tomography
(PET) is higher in patients with acute coronary syndromes (ACS) than in
patients with stable coronary artery disease (CAD) and; 2) associated with
morphological markers of plaque instability detected with computed tomo-
graphy angiography (CTA).
Methods: Patients with ACS (n=50) or stable CAD (n=28) underwent a
PET 90 minutes after injection of 5 MBq/kg FDG followed by a CTA of the
thoracic aorta and carotid arteries. Tissue-to-background ratios (TBRs) were
calculated by dividing maximal standard uptake value (SUV) of the arterial
wall by the mean SUV of blood. A global TBR was calculated in each patient
as the average of the TBRs from the thoracic aorta and the 2 carotid arteries.
Atherosclerotic plaques were classified with CTA as non-calcified/mixed/cal-
cified, and smooth/irregular.
Results: Aortic, carotid and global TBRs (mean±SD) were higher in
patients with ACS than in patients with stable CAD (1.78±0.19 vs. 1.61±0.18;
1.84±0.35 vs. 1.64 ±0.17; 1.81±0.23 vs. 1.62±0.16; p<0.05 for all). Patients in
the highest quartile of global TBR had a higher percentage of non-calcified
and irregular plaques in the thoracic aorta and carotid arteries as compared to
patients in the lowest quartile of global TBR (cf. Table 1).
Conclusions: FDG uptake in the thoracic aorta and carotid arteries is
higher in patients with ACS than in patients with stable CAD and correlates
with morphological markers of plaque instability assessed by CTA.
Table 1 – Results
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Objectives: Define echocardiographic predictors of the immediateresults
of percutaneous mitral balloon commissurotomy (PMC)
Methods : PMC by the Inoue balloon was attempted in 247 patients (mean
age: 35 ans, 77% female) with severe mitral valve stenosis. All the patients
had undergone echocardiographic examination before PMC to assess mitral
anatomy, commissural calcification and to determine the Wilkins score.
Results: the mean value of Wilkins score was 7,98±1,61(range 5-13) and
the mean mitral valve area (MVA) before PMC was 1±0,19cm² (range 0,5-
1,4cm²). Twenty-nine patients (11,7%) had one-commissural calcification.
After PMC, the mean MVA increased to 1,79±0,34cm² (p<0,001) resulting in
a success rate of 83%. Severe mitral regurgitation (MR) occured in 5 patients
(2%). Wilkins score was an independent predictor of the immediate result of
PMC, but if >8, this score had a weak predictive value. Commissural mor-
phology was another independent predictor of the immediate result of PMC.
Conclusion: Echocardiography is now the cornerstone in the assessment of
mitral anatomy before PMC and should integrate Wilkins score and commis-
sural morphology for the optimal selection of patients to PMC.
*This abstract refered to topic “Valvular heart disease”.
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Background: Acute complications of atherosclerosis, such as acute myo-
cardial infarction (AMI) are becoming more common in patients with HIV.
But the risk of coronary heart disease in HIV patients is influenced both from
traditional risk factors and from specific features of this disease. The aim of
the present study was to examine in-hospital case fatality in HIV-infected
patients with AMI.
Methods: From the French nationwide hospital medical information data-
base, data for all the consecutive patients hospitalized in the 1546 French hos-
pital/clinics for AMI from 1st January 2005 to 31st December 2009 were
analysed. Patients were match according
following parameters: age, gender, type of infarction (ratio 1:2).
Findings: Among the 677 076 patients included, HIV-infected patients
(n=1344) accounted for 0.20%. HIV patients were younger, more frequently
male and more likely to smoke. Hospital mortality was 4.3% in the HIV-
infected group compared with 7.0% in uninfected patients (p <0.0001), but no
difference appeared between the 2 groups after matching (3.4% vs. 4.3%;
p=0.1334). Based on a Cox regression model, HIV-infection was not an inde-
pendent predictor of in-hospital mortality in the overall population or after
matching. Among none HIV infected patients, dyslipidemia, current smoker,
STEMI and coronary angioplasty were independent predictors of in-hospital
mortality. In contrast, among HIV infected patients, dyslipidemia [OR-95%IC:
0.356 (0.141-0.903)], renal failure [OR-95%IC: 2.433 (1.174-5.044)] and
STEMI [OR-95%IC: 2.130 (1.113-4.076)] were independent factors were
associated with in-hospital mortality.
Conclusion: HIV-infected patients have a greater risk of myocardial
infarction, but the present study demonstrated than the short-term are similar
to non infected patients. Moreover, chronic kidney disease is more common in
HIV-infected patients and associated with a worse prognosis. Consequently
HIV care increasingly needs to incorporate strategies to manage these non-
infectious co-morbidity in primary and secondary prevention.
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Background: The national observational study of diagnostic and interven-
tional cardiac catheterization (ONACI) is a prospective multi-center registry
of the French Society of Cardiology including all interventional cardiology
procedures performed from 2004. We aimed to evaluate “real world” manage-
ment of patients with coronary artery disease (CAD) in France from this
registry.
Methods: The present study is focused on data collected between 2004 and
2008. Patient demographics and co-morbidities, invasive parameters, treat-
ment options, and procedural techniques were prospectively collected. Patients
were recruited in 99 hospitals (55% of patients were hospitalized in private
clinics, 45% in public institutions).
Total 
number 
of 
plaques
Global 
TBR 
values
Patients 
with 
ACS
on 
calcified
MixedCalcifiedSmooth Irregular
First 
quartile
53 1.36-1.60 32% 30% 45% 25% 100% 0%
Second 
quartile
70 1.61-1.70 63% 43% 37% 20% 94% 6%
Third 
quartile
55 1.71-1.81 74% 39% 47% 14% 87% 13%
Forth 
quartile
58 1.82-2.75 85% 40% 57 % 3% 88% 12%
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Results: Over a 5-year period, a total of 298,105 patients underwent coronary
angiography (CAG) and 176,166 patients underwent percutaneous coronary inter-
vention (PCI). Diagnosis was acute coronary syndrome (ACS) in 22%, stable
angina or silent ischemia in 23% and atypical chest pain in 9% of cases. Normal
coronary arteries or not significant coronary lesions were found in 26% of patients.
Radial access was increasingly used over the years regardless of the indication.
The average number of PCI per procedure was 1.5±0.7 (range from 1.3±0.7 to
1.5±0.7) and those of stents per procedure were 1.5±0.8 (range from 1.5±0.8 to
1.6±0.8). Drug-eluting stents (DES) were used in 45% (range from 34 to 62%).
Conclusions: Coronary anatomy is highly dependent on clinical presenta-
tion. Strategies to reduce the number of normal CAG performed for atypical
chest pain should be developed. The management of ACS is associated with
less radial access, more single PCI and fewer DES.
020
Impact of anti-platelets dose fractionation on platelet inhibition in
type 2 diabetes mellitus
Redouane Saady, Denis Doyen, Emile Ferrari
CHU ice, Cardiologie, ice, France
Objective: The hypothesis of the study was that increased drug administra-
tion frequency [twice daily versus once daily] may provide more effective
platelet inhibition in patients with type 2 diabetes mellitus.
Methods: Twenty patients with type 2 diabetes mellitus with stable coro-
nary artery disease were prospectively recruited. All the patients received once
daily 150 mg of aspirin and clopidogrel for two weeks. Then patients were
switched to aspirin and clopidogrel 75 mg twice daily for two weeks. Pharma-
codynamic assessment was performed by VerifyNow system accumetrics at
fifteen and thirty days.
Results: There was no difference between the antiplatelet effect produced
by 150 mg of aspirin given once daily and 75 mg of aspirin given twice daily.
A twice-daily dose of 75 mg of clopidogrel is associated with significantly
more effective platelet inhibition on the residual assay: PRU=38.2% once
daily vs 53.8% twice daily (p= 0.001) and PRU=187 once daily vs 147 twice
daily (p=0.005). 
Conclusions: Increasing the frequency of clopidogrel administration to
twice daily in patients with type 2 diabetes mellitus is significantly associated
with more effective platelet inhibition. But our data do not support a twice-
daily dose of aspirin to improve platelet response.
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Background: Clopidogrel low response correlates with poor prognosis
after percutaneous coronary intervention (PCI). Many biological tests are cur-
rently available to test the clopidogrel response. However, the presence of any
correlation between the different tests is today poorly reported.
Methods: In this prospective study, clopidogrel response was assessed in
100 consecutive patients. All patients were tested between 18h and 24h after
a 600mg clopidogrel loading dose using 3 different tests: light transmission
aggregometry with 10 µmol ADP (LTA, results expressed as platelet inhibi-
tion percentage), VerifyNow-P2Y12 (VN, results expressed as PRU) and
vasodilatator stimulated phosphoprotein (VASP, results expressed as IRP).
Patients under chronic clopidogrel therapy were excluded.
Results: The mean platelet inhibition percentage, PRU value and IRP value
were 38.5±13% by LTA, 178±89 PRU by VN and 52±21% by VASP. When
results were analyzed as continuous variables, there was a good correlation
between the different tests: LTA/VN (R2=0,642, p<0,001), LTA/VASP
(R2=0,409, p<0,001) and VN/VASP (R2=0,616, p<0,001). However, when
results were analyzed as pre-specified cut-off points to define patients as “low
or good responders” (according to the literature: 50% for LTA, 235 PRU for VN
and 50% IRP for VASP), only 47% of the patients were defined as “good” or
“low responders” by the 3 tests. Altogether, 33% of the patients were defined as
“low responders” by only 1 test, 20% by 2 tests and only 16% by the 3 tests.
Conclusion: If the correlation between the different tests is good when
results are analyzed as continuous variables, each individual is rarely (less
than 50%) defined as “low or good responder” by all the 3 tests when reco-
gnized cut-off values are used. In that way, a sole test might not be sufficient
to manage antiplatelet therapy in an individual patient.
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Background: Low-molecular-weight heparins have recently been intro-
duced in the management of ST elevation myocardial infarction (STEMI)
patients but evidence remains poor among specific populations particularly
elderly and patients with renal dysfunction.
Objective: to compare the outcome (mortality and hemorrhage) between
patients treated with unfractionned heparin (UFH) versus low-molecular-
weight heparins (LMWHs) in the whole population and among elderly and
renal dysfunction patients.
Methods: Patients admitted for STEMI between January 1995 and
November 2011 were retrospectively enrolled in the MIRAMI (MonastIR
Acute Myocardial Infarction) registry. We compared the outcome (mortality
and hemorrhage) between patients who received UFH versus LMWHs in the
global MIRAMI population, then among elderly (aged over 75 years) and
renal dysfunction patients (defined by a creatinin level >130 µmol/l).
Résultats: UFH was more often used when thrombolysis was adopted as
reperfusion therapy (80.6% vs 68.6% when primary angioplasty is adopted,
p<0.001), when patients present with heart failure (p<0.001), among elderly
(p<0.001) and in patients with renal dysfunction (p=0.002). High rates of pre-
scription of UFH may be attributed to the enrollment of patients since 1995,
before LMWHs introduction in clinical practice. Mortality was higher among
patient treated with UFH. This difference was statistically significant in the
global population (11.9% vs 3.1%, p<0.001), but there was no significant dif-
ferences among elderly (22.3% and 13.3%, p=0.65) and in renal dysfunction
patients (39% vs 20%, p=0.23). Use of LMWHs did not show an increase of
hemorrhagic complications in the global population (p=0.118), among elderly
(p=0.45) nor renal dysfunction patients (p=0.61).
Conclusion: In the MIRAMI registry, LMWHs seemed to be at least as
safe and effective as UFH in STEMI patients, even in elderly or renal dys-
function population.
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Background: The national observational study of diagnostic and interven-
tional cardiac catheterization (ONACI) is a prospective multi-center registry
